Exane Derivatives’s NovoCure NVCR Stock Holding History

Exane Derivatives’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$208	Sell	3 -786	-100%	-$59.2K	﹤0.01%	670
2022 Q1	$65.4K	Sell	789 -161	-17%	-$11.9K	0.02%	538
2021 Q4	$71.3K	Sell	950 -284	-23%	-$28.5K	0.02%	469
2021 Q3	$143K	Sell	1,234 -204	-14%	-$30.8K	0.03%	471
2021 Q2	$271K	Sell	1,438 -452	-24%	-$87.9K	0.06%	316
2021 Q1	$250K	Sell	1,890 -819	-30%	-$130K	0.07%	266
2020 Q4	$469K	Buy	+2,709	New	+$371K	0.14%	172

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Exane Derivatives's NVCR Position: Q2 2022 in Review

Exane Derivatives reduced its NovoCure (NVCR) stake by 100% in Q2 2022, selling an estimated $59.2K and leaving 3 shares worth $208. The position accounts for ﹤0.01% of the portfolio, ranked #670.

Exane Derivatives first reported a position in NVCR in Q4 2020 and has held it in 7 quarters since. The position peaked at $469K in Q4 2020. 317 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Exane Derivatives held 3 shares of NovoCure worth $208 as of Q2 2022.
Exane Derivatives sold 786 NovoCure shares in Q2 2022, an estimated $59.2K.
NovoCure made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #670 holding.
Exane Derivatives first reported a position in NovoCure in Q4 2020 and has held it in 7 quarters since.
Exane Derivatives's NovoCure position peaked at $469K in Q4 2020.
317 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.